India's specialty chemicals sector is entering a new China+1 phase, with companies moving beyond simple export diversification to higher-value products and contract manufacturing. According to The Financial Express, the first wave came in 2020-22 during pandemic-driven supply disruptions, but this shift appears more structural as global customers diversify suppliers while Indian companies advance up the value chain from commodity chemicals to specialized molecules and high-value applications. Three small-cap specialty chemical companies - Yasho Industries, Privi Speciality Chemicals, and Aether Industries - represent different approaches to capitalizing on this structural shift. As per Screener.in, the opportunity is getting even broader across the specialty chemicals value chain, with global customers looking beyond China for reliable suppliers while Indian chemical makers are growing more resilient.
Yasho Industries is emerging as a standout recovery story in India's specialty chemicals space, with its businesses historically facing pricing pressure from Chinese oversupply. The company manufactures specialty and performance chemicals for rubber, lubricants, pharmaceuticals, food, and fragrances, with revenue growing 23% to ₹830 crore in FY26 and net profit more than quadrupling to ₹25 crore. In Q1FY27, consolidated revenue rose 55% YoY to ₹308 crore with net profit expanding to ₹36 crore, while EBITDA margin improved significantly to 24.2% from 16.5% in Q1FY26. The company has doubled its FY27 capex plan to ₹250 crore and targets 30-40% annual revenue growth with 65% of new capacity backed by customer commitments. During the quarter, Yasho generated 69% of its revenue from exports and 31% from India, with the company's bank loan ratings upgraded by CRISIL and ICRA from BBB+ to A-.
Privi Speciality Chemicals operates at around 90% capacity utilization with strong relationships with global fragrance, personal-care, and FMCG companies. The company achieved 22% revenue growth to ₹2,564 crore in FY26 with EBITDA margin expanding to 25.8%, while Q1FY27 showed 19.2% revenue growth to ₹666 crore with net profit increasing 44% to ₹82.8 crore. Management has outlined a '5K:1K' ambition targeting ₹5,000 crore revenue and over ₹1,000 crore EBITDA over the next three to four years, while significantly improving working capital cycle to 108 days from 141 days and achieving 21.7% Return on Capital Employed. The company has doubled its FY27 capex plan to ₹250 crore and targets 30-40% annual revenue growth with 65% of new capacity backed by customer commitments.
Aether Industries is transitioning toward higher-value contract manufacturing, with CEM and CRAMS now contributing around 60% of revenue and management targeting 70% share over the next two years. The company achieved 38% revenue growth to ₹1,160 crore in FY26 with EBITDA margin expanding to 30.3%, while Q1FY27 showed 27.3% revenue growth to ₹327 crore with EBITDA margin improving to 31.5%. Notably, Aether announced a multi-year exclusive research collaboration with Dow Chemical to develop manufacturing technologies for foundational silicones, targeting the $1 billion domestic market currently import-dependent. The company's diversified portfolio spans pharmaceuticals (32.2%), oil and gas (31.4%), and agrochemicals (9.5%), with the company expanding into newer markets and targeting semiconductor and AI supply chain applications. The shift toward exclusive manufacturing is particularly important as CEM generates EBITDA margins of around 28-30%.
The three companies show significant valuation differences, with Yasho trading at 94x trailing earnings - more than twice its five-year median of 40.1x - while Privi appears more reasonably valued at 38.8x earnings below its five-year median of 54.4x. Aether trades at 90.9x earnings near its five-year median of 88.4x, with the key question being whether its CEM/CRAMS transition can deliver the earnings growth needed to support high multiples. All three stocks have rallied substantially - Yasho up 125%, Privi up 120%, and Aether up 120% over the past year - reflecting investor optimism about the China+1 opportunity and execution capabilities of these specialty chemical manufacturers. As per Screener.in, Yasho is the biggest re-rating story with the market pricing in strong earnings growth and sustained margins, while Aether's P/E is close to its five-year median, making it the most reasonably valued among the three.
